These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29052427)

  • 21. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force.
    Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ
    Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):44-55. PubMed ID: 36215113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference.
    Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):305-7. PubMed ID: 19670989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force.
    Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ
    Value Health; 2022 Oct; 25(10):1663-1672. PubMed ID: 36241338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.
    Solow B; Pezalla EJ
    Value Health; 2018 Feb; 21(2):166-168. PubMed ID: 29477395
    [No Abstract]   [Full Text] [Related]  

  • 29. ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.
    Sculpher M
    Value Health; 2018 Feb; 21(2):171-172. PubMed ID: 29477397
    [No Abstract]   [Full Text] [Related]  

  • 30. ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.
    Burkholder R; Dougherty JS; Neves LA
    Value Health; 2018 Feb; 21(2):173-175. PubMed ID: 29477398
    [No Abstract]   [Full Text] [Related]  

  • 31. ISPOR Code of Ethics for Researchers background article--report of the ISPOR Task Force on Code of Ethics for Researchers.
    Palumbo FB; Barnes R; Deverka P; McGhan W; Mullany L; Wertheimer A;
    Value Health; 2004; 7(2):111-7. PubMed ID: 15164801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
    Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
    Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A translation table for patient-centered comparative effectiveness research: guidance to improve the value of research for clinical and health policy decision-making.
    Tunis SR; Messner DA; Mohr P; Gliklich RE; Dubois RW
    J Comp Eff Res; 2012 May; 1(3):259-62. PubMed ID: 24237407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
    Mycka JM; Dellamano R; Kolassa EM; Wonder M; Ghosh S; Hay JW; Smeeding J
    Value Health; 2010; 13(1):25-7. PubMed ID: 19883402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting (May 17-20, 2021 - Virtual Meeting).
    Kibble A
    Drugs Today (Barc); 2021 Aug; 57(8):519-525. PubMed ID: 34405209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force.
    Bridges JF; Hauber AB; Marshall D; Lloyd A; Prosser LA; Regier DA; Johnson FR; Mauskopf J
    Value Health; 2011 Jun; 14(4):403-13. PubMed ID: 21669364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interview: A private sector life in comparative effectiveness research. Interview with Robert W Dubois.
    Dubois RW
    J Comp Eff Res; 2013 Sep; 2(5):429-31. PubMed ID: 24236739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
    Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A
    Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.